AgingResearch.NewsJoin free

Engineered extracellular vesicles delivering cas9/sgrna and surface pd-1/angiopep-2

Intervention

1 paper3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

  • 1 lab in 1 country
  • Funder: National Natural Science Foundation of China
  • Animals1

Outcomes

3

CD8-positive T cell activation

upin animals1

1 study

  1. Engineered extracellular vesicles delivering cas9/sgrna and surface pd-1/angiopep-2 activates CD8-positive T cell activation.

    “These modified EVs were then utilized to rejuvenate exhausted CD8+ T cells blocking PD-L1”

    Animalsblocking PD-L1

    Synergistic strategies for glioblastoma treatment: CRISPR-based multigene editing combined with immune checkpoint blockade

    Journal of nanobiotechnology7 Feb 2025

Angiogenesis

downin animals1

1 study

  1. Engineered extracellular vesicles delivering cas9/sgrna and surface pd-1/angiopep-2 inhibits angiogenesis.

    “demonstrating an antiangiogenic effect.”

    Animalsin vivo

    Synergistic strategies for glioblastoma treatment: CRISPR-based multigene editing combined with immune checkpoint blockade

    Journal of nanobiotechnology7 Feb 2025

More on Angiogenesis

Apoptosis

upin animals1+59%

1 study

  1. Engineered extracellular vesicles delivering cas9/sgrna and surface pd-1/angiopep-2 induces apoptosis (58.6%).

    “The multigene editing of EVs resulted in efficient intratumor multisite gene editing (PLK1: 58.6%, VEGF: 52.7%), leading to the successful apoptosis of tumor cells in vivo”

    Animalsin vivo

    Synergistic strategies for glioblastoma treatment: CRISPR-based multigene editing combined with immune checkpoint blockade

    Journal of nanobiotechnology7 Feb 2025

More on Apoptosis

Latest

Related